2019
DOI: 10.1097/01.hs9.0000561596.81498.79
|View full text |Cite
|
Sign up to set email alerts
|

S829 Sotatercept (Ace‐011) in Subjects With Mpn‐associated Myelofibrosis and Anemia

Abstract: Background:Anemia is common in myelofibrosis (MF) and current treatments are unsatisfactory. Anemia is not improved, and often initially worsened by ruxolitinib (rux), the only approved treatment for MF. Sotatercept is a first‐in‐class, activin receptor IIA (ActRIIA) “ligand trap” that sequesters ligands that bind to the ActRIIA, some of which inhibit terminal erythropoiesis.Aims:To evaluate the efficacy and safety of sotatercept in anemic subjects with MF, alone and with rux.Methods:This ongoing, single‐insti… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2020
2020
2020
2020

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 0 publications
0
3
0
Order By: Relevance
“…Results from 13 evaluable patients receiving the combination of sotatercept and ruxolitinib were presented at the European Hematology Association (EHA) Annual Meeting in 2019. Three (23%) patients achieved an anemia response, defined as 1.5 g/dL increase in hemoglobin for ≥12 weeks or conversion from transfusion dependence to transfusion independence [ 34 ]. Luspatercept is being evaluated in a multicenter, phase 2 study of MF patients as a single-agent and in combination with ruxolitinib (NCT03194542).…”
Section: Killing Two Birds With Two Stones: Efforts To Manage Anemmentioning
confidence: 99%
“…Results from 13 evaluable patients receiving the combination of sotatercept and ruxolitinib were presented at the European Hematology Association (EHA) Annual Meeting in 2019. Three (23%) patients achieved an anemia response, defined as 1.5 g/dL increase in hemoglobin for ≥12 weeks or conversion from transfusion dependence to transfusion independence [ 34 ]. Luspatercept is being evaluated in a multicenter, phase 2 study of MF patients as a single-agent and in combination with ruxolitinib (NCT03194542).…”
Section: Killing Two Birds With Two Stones: Efforts To Manage Anemmentioning
confidence: 99%
“…23 Sotatercept was studied both as monotherapy and in patients on a stable dose of ruxolitinib. 24 The response rate, a combination of transfusion independent (TI) by IWG-MRT criteria and anemia response by Gale criteria, was 35% in patients treated with sotatercept alone and 12.5% in patients treated with the combination of sotatercept and ruxoloitinib. 25 Grade 3 treatment-emergent adverse events (TEAEs) were limited to hypertension and limb pain.…”
Section: Activin Receptor Ligand Traps For the Treatment Of Anemia mentioning
confidence: 99%
“…Eligible patients had to be anemic or transfusion‐dependent (TD) per International Working Group for Myelofibrosis Research and Treatment (IWG‐MRT) criteria 23 . Sotatercept was studied both as monotherapy and in patients on a stable dose of ruxolitinib 24 . The response rate, a combination of transfusion independent (TI) by IWG‐MRT criteria and anemia response by Gale criteria, was 35% in patients treated with sotatercept alone and 12.5% in patients treated with the combination of sotatercept and ruxoloitinib 25 .…”
Section: Activin Receptor Ligand Traps For the Treatment Of Anemia Asmentioning
confidence: 99%